Surfix receives investment of 8.5 million euros for further development of their plug and play diagnostics platform

Published on
June 9, 2021

Surfix, a spin-off company of Wageningen University & Research and located on Wageningen Campus, has received an investment from a Dutch consortium consisting of the companies Qurin Diagnostics and LioniX International, industry accelerator PhotonDelta and the East Netherlands Development Agency for further development of Surfix’s plug- and-play diagnostic platform.

Surfix will use the investment to accelerate the development of its fast, reliable and attractive plug-and-play diagnostics platform for all sorts of point-of-care tests. The initial target applications are early cancer diagnosis,  Covid-19 detection and tracing of pathogens in water for aquaculture.

Read more